Cabaletta Bio Inc (CABA)

Cabaletta Bio Inc (CABA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $251M; returns 1 day -3.3%, 1 week +4.3%, 1 year -39.0%.

Cabaletta Bio is a clinical-stage biotechnology company pioneering the application of chimeric antigen receptor (CAR) T cell therapies for autoimmune diseases. The company's business model is pre-revenue, with operations currently funded through capital raises and interest income.

Groups CABA belongs to

• Biotechnology
• Autoimmune Diseases
• Clinical Stage Biotech
• Healthcare
• Biopharmaceutical
• Clinical Stage
• R&D
• Precision Medicine
• Life Sciences
• Unmet Medical Needs

CABA financial model: income statement, cash flow and balance sheet